If a person's cell have the antigen, the antibody should NOT be present in that person's serum. If an antibody to a blood group antigen is present in the serum of a person, his or her cells should lack that antigen. The antigens are on the cells and the antibodies are in the serum.
Therapy-related myeloid leukemia (t-MDS/t-AML) is a well-recognized clinical syndrome occurring as a late complication following cytotoxic therapy.1â5 The term âtherapy-relatedâ leukemia is descriptive and based on a patientâs history of exposure to cytotoxic agents.
Highlights. â¢ 1 AML subclones are discrete, genetically distinct entities in AML samples. â¢ 2 AML subclones often have unique functional and morphological properties. â¢ 3 Engraftment of AML cells in mice is not defined by evolutionary hierarchy. â¢ The AML founding clone is not equivalent to the AML-initiating cell in mice.